Quantum BioPharma Launches C$4M Convertible Debenture Offering with 1.25% Monthly Interest
Quantum BioPharma will release its Q4 and full-year 2025 results on March 24, 2026. The company plans a non-brokered private placement of up to 4,000 convertible debentures at C$1,000 each bearing 1.25% monthly interest with 250 warrants per unit and will settle debt by issuing shares at C$4.
1. Q4 and Full-Year 2025 Results Release
Quantum BioPharma will publish its financial and operational results for the quarter and fiscal year ended December 31, 2025 after markets close on March 24, 2026. These results will detail revenue, R&D expenses, and cash position available on SEDAR+, EDGAR, and the company’s website.
2. Private Placement Offering Details
The company intends to issue up to 4,000 secured convertible debenture units at C$1,000 each, raising up to C$4 million. Each unit carries 1.25% monthly interest, payable quarterly, and includes 250 warrants exercisable at C$5 over five years, with conversion into shares at C$4 per share.
3. Debt Settlement Arrangement
Quantum BioPharma will settle certain creditor obligations by issuing shares at the C$4 conversion price, including amounts owed to insiders. The transaction relies on exemptions under MI 61-101 as neither the fair market value of the transaction nor its consideration exceeds 25% of market capitalization.